Editorial: Diagnosis of COVID-19 in Countries with Limited Health Resources – Blood Markers versus rRT–PCR



[1] Lippi, G., Mattiuzzi, C., Bovo, C., et al. (2020). Current laboratory diagnostics of coronavirus disease 2019 (COVID-19). Acta Biomedica, vol. 91, no. 2, pp. 137–145.

[2] Cohen, J. and Kupferschmidt, K. (2020). Countries test tactics in ‘war’ against COVID-19. Science, vol. 367, no. 6484, pp. 1287–1288.

[3] Velavan, T. P. and Meyer, C. G. (2020). Mild versus severe COVID-19: laboratory markers. International Journal of Infectious Diseases, vol 95, pp. 304–307.

[4] Santotoribio, J. D., Nuñez-Jurado, D., and Lepe-Balsalobre. E. (2020). Evaluation of routine blood tests for diagnosis of suspected coronavirus disease 2019. Clinical Laboratory, vol. 66, no. 9.

[5] Ferrari, D., Sabetta, E., Ceriotti, D., et al. (2020). Routine blood analysis greatly reduces the false-negative rate of RT-PCR testing for COVID-19. Acta Bio Medica, vol. 91, no. 3, e2020003.

[6] Ibnouf, A.-A. O., Khalil, M. H., Khalid, R., et al. (2020). Blood markers (lymphocyte percentages, neutrophils, CRP and ESR) can help in prioritizing rRT-PCR test for suspected COVID-19 patients in countries with limited health resources. Pan African Medical Journal, vol. 37, p. 331.